Can hydralazine (antihypertensive medication) cause flaky skin in patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Hydralazine Cause Flaky Skin?

Hydralazine does not typically cause simple flaky skin, but it can cause serious cutaneous reactions including bullous lesions, ulcerative rashes, and toxic epidermal necrolysis as manifestations of drug-induced lupus or ANCA-associated vasculitis.

Documented Cutaneous Reactions to Hydralazine

The skin manifestations associated with hydralazine are generally severe and distinct from simple flaky skin:

Serious Cutaneous Manifestations

  • Bullous lupus erythematosus has been documented with hydralazine use, presenting as blister-type lesions with hemorrhagic bullae affecting oral, nasal, and conjunctival mucosa 1

  • Toxic epidermal necrolysis (TEN) has been reported, characterized by well-demarcated erythematous maculopapular rashes that transform into bullous lesions with widespread erythema and necrosis 2

  • Diffuse bullous and ulcerative lesions can occur as part of hydralazine-induced ANCA vasculitis, presenting with severe cutaneous involvement 3

  • Lower extremity petechiae is commonly seen (in 67% of cases) as part of hydralazine-associated vasculitis 4

Drug-Induced Lupus Presentation

  • The American College of Cardiology/American Heart Association guidelines note that hydralazine is "associated with drug-induced lupus-like syndrome at higher doses," typically above 150-200 mg daily 5

  • Classic lupus cutaneous manifestations include malar or discoid rash rather than simple flaky skin 1

  • Skin involvement typically occurs alongside systemic features including cardiopulmonary manifestations, with most patients exposed to hydralazine for more than 12 months before developing symptoms 6

Clinical Context and Risk Factors

  • The mean age at diagnosis of hydralazine-induced lupus is 62 years, with the majority of patients exposed to the medication for more than 12 months 6

  • The mean cumulative dose associated with vasculitis is approximately 146 grams over an average duration of 22 months 4

  • Patients typically present with constitutional symptoms (dyspnea, fatigue, unintentional weight loss) alongside cutaneous findings rather than isolated skin changes 4

Important Clinical Pitfall

If a patient on hydralazine develops any new skin lesions—even if they appear as simple flaky skin—consider more serious underlying pathology. The cutaneous manifestations of hydralazine-induced autoimmune disease can begin subtly but progress rapidly to severe bullous or ulcerative lesions 2. Immediate discontinuation of hydralazine is the mainstay of therapy for any suspected drug-induced cutaneous reaction 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.